Despite progressive advances, therapy with interferon and ribavirin has been the mainstay of treatment for chronic hepatitis C for over a decade. With the development of in vitro systems to study viral replication, there have been great advances in the understanding of hepatitis C biology, and these advances, in turn, are allowing the development of specifically targeted antiviral therapies. This review employs our current understanding of the hepatitis C replicative life cycle as a framework on which to discuss new antiviral agents under clinical investigation.
|Original language||English (US)|
|Number of pages||8|
|Journal||Current Hepatitis Reports|
|State||Published - May 2007|
ASJC Scopus subject areas